This product is a CRISPR/Cas9-edited polyclonal knockout cell population of the SK-HEP-1 liver adenocarcinoma cell line, engineered to disrupt the human ARPC1B gene. ARPC1B encodes the p41-Arc subunit of the Arp2/3 complex, a critical nucleator of branched actin filaments. The polyclonal nature of this knockout model reflects a heterogeneous pool of cells harboring distinct CRISPR-mediated gene disruptions, avoiding monoclonality artifacts. The SK-HEP-1 host cells were derived from ascites fluid of a male patient with liver adenocarcinoma and display adherent, epithelial-like morphology along with endothelial markers, offering a widely used hepatic cancer model.
The SK-HEP-1 cell line serves as a robust model for hepatocellular carcinoma research, particularly for investigating liver carcinogenesis, metastatic progression, and drug response. Originating from a liver adenocarcinoma patient, these cells exhibit an adherent, epithelial phenotype and express markers typically associated with endothelial cells, such as factor VIII-related antigen, which distinguishes them from other hepatoma lines. This unique background provides a versatile platform for studying tumor cell behavior in the context of both hepatic and vascular-mimicking microenvironments, making it highly relevant for cancer biology, pharmacology, and immunology studies.
ARPC1B is a core subunit of the Arp2/3 complex, which is activated by nucleation-promoting factors such as WASP, N-WASP, and the WAVE regulatory complex, downstream of Cdc42, Rac1, and receptor tyrosine kinases. It interacts directly with ARPC2-5, ACTR2/3, and actin, driving branched filament formation essential for lamellipodia extension, cell migration, and endocytic vesicle scission. Disruption of ARPC1B impairs F-actin polymerization and compromises pathways including phagocytosis, integrin clustering, and invadopodia formation.
In the SK-HEP-1 liver cancer context, ARPC1B knockout profoundly impacts actin cytoskeleton dynamics that are essential for tumor cell invasion and metastatic behavior. Loss of p41-Arc disrupts the efficient formation of branched actin networks, leading to diminished lamellipodial extension and reduced migration capacity, as can be assessed by wound healing and Transwell assays. Additionally, endocytic trafficking, an integral process for receptor recycling and signal attenuation in hepatocellular carcinoma, may be compromised. This model thereby recapitulates aspects of ARPC1B-related combined immunodeficiency, a condition marked by defective leukocyte chemotaxis and actinopathy, and provides a valuable tool for dissecting the link between actin remodeling and cancer aggressiveness in a liver-specific cellular background.
Researchers can leverage this polyclonal knockout cell pool for diverse experimental applications, including investigating actin polymerization dynamics in hepatocellular carcinoma, screening for small molecules that target the Arp2/3 complex, and evaluating anti-metastatic therapeutic strategies. Representative assays include phalloidin staining to visualize F-actin structures, immunofluorescence for Arp2/3 complex localization, quantitative migration and invasion assays, phagocytosis measurement, flow cytometry for integrin surface expression, and live-cell imaging to monitor lamellipodia behavior. Transcriptomic profiling via RNA-seq can further characterize compensatory mechanisms. For further details on this product, please contact Ascent Research.
